# Passage BIO, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Passage BIO, Inc.). ## Overview Passage BIO, Inc. is a U.S.-based clinical-stage genetic medicines company focused on developing one-time gene therapies for neurodegenerative diseases. The company was incorporated in Delaware and is centered on advancing licensed technology, conducting clinical trials, and manufacturing clinical supply for its product candidates. ## Products & services • PBFT02 gene therapy for neurodegenerative disease • AAV1-based gene replacement platform • Preclinical research and translational development • Clinical trial execution and clinical supply manufacturing • Licensed CNS gene therapy technology - **Clinical-stage gene therapy candidates** (0%) — One-time genetic medicines designed to treat neurodegenerative diseases, including PBFT02. - **Preclinical and translational development** (0%) — Research, assay development, and preclinical studies supporting pipeline advancement. - **Clinical trial supply and manufacturing** (0%) — Manufacturing of clinical-grade material and supply for ongoing trials. - **Licensed technology development** (0%) — Development and use of in-licensed intellectual property for CNS gene therapy programs. - PBFT02 gene therapy for neurodegenerative disease - AAV1-based gene replacement platform - Preclinical research and translational development - Clinical trial execution and clinical supply manufacturing - Licensed CNS gene therapy technology ## Customers Passage BIO’s direct customers are not commercial end-users today; its work is aimed at regulators, clinical investigators, and eventually physicians and patients in neurodegenerative disease markets. In the current stage, the company’s economic value is tied to advancing product candidates through clinical development and generating data that can support future partnering or commercialization. - **Clinical investigators and trial sites** (primary) — They run studies of PBFT02 and related programs and need clinical supply, protocols, and support. - **Regulators** (primary) — FDA and other agencies evaluate the company’s clinical and manufacturing data for approval pathways. - **Future patients with neurodegenerative disease** (primary) — The eventual end users of approved gene therapies for CNS disorders such as frontotemporal dementia. - **Potential strategic partners** (secondary) — Biopharma collaborators or licensors that may support development, funding, or commercialization. - Clinical investigators running neurodegenerative disease trials - Regulators reviewing safety and efficacy data - Future physicians treating CNS genetic disorders - Future patients with frontotemporal dementia and related diseases - Potential collaborators or license partners ## Geography Passage BIO is incorporated in Delaware and operates as a U.S.-based development-stage biotechnology company. Its clinical and manufacturing activities are centered on the United States, while future commercialization would depend on regulatory and reimbursement conditions in the U.S. and other markets. - Incorporated in Delaware, United States - Clinical development and operations are U.S.-based - Manufacturing supply currently relies on third-party U.S. facilities - Future market access would depend on U.S. and international reimbursement - No country revenue disclosure is available because the company is pre-commercial ## Strategy The company’s strategy is to advance PBFT02 and other gene therapy programs through clinical development, with a focus on neurodegenerative diseases and CNS delivery. It also seeks to preserve flexibility through collaborations, in-licensing, and other strategic transactions while it funds development through external capital. - **Advance PBFT02 clinical development** (short-term) — Clinical data are the main driver of value for a pre-commercial gene therapy company. - **Secure additional capital** (short-term) — Development-stage operations require external funding before product revenue exists. - **Strengthen manufacturing and assay capabilities** (medium-term) — Gene therapies require validated, reproducible manufacturing and release testing. - Advance PBFT02 through clinical development - Build evidence for CNS gene therapy in neurodegenerative disease - Use licensed technology to target differentiated biology - Rely on collaborations and capital raises to fund operations - Evaluate strategic transactions to extend the pipeline ## Risks Passage BIO faces the typical risks of a clinical-stage biotechnology company: clinical failure, regulatory delay, manufacturing complexity, and the need for repeated external financing. Because it has no commercial product revenue, its business model is highly dependent on successful trial outcomes, access to capital, and eventual reimbursement for any approved therapy. - **Single-program concentration** [high] — PBFT02 is currently the only clinical-stage product candidate, so setbacks would have outsized impact. - **Clinical development failure** [high] — Gene therapy programs can fail on safety, efficacy, dosing, or delivery even after early promise. - **Manufacturing and supply chain disruption** [high] — The company relies on third parties for clinical supply, testing, and process development. - **Financing risk** [high] — Operations are funded through external capital until product revenue, if any, is generated. - **Reimbursement and market access risk** [medium] — Even if approved, payors may limit coverage or pricing for high-cost gene therapies. - PBFT02 is the sole clinical-stage candidate - Clinical trials may fail or not show sufficient efficacy - Gene therapy manufacturing is complex and may disrupt timelines - Additional capital will be needed before profitability - Future reimbursement may be limited or uncertain ## Accounting The most important accounting issues are R&D expense recognition, clinical trial and manufacturing accruals, and valuation of any licensed or acquired intangible assets. As a pre-revenue biotech, reported losses are driven largely by development spending, while judgments around milestone timing, third-party invoices, and potential impairment can materially affect period-to-period results. - **Research and development expense recognition** — Clinical trial, manufacturing, and development costs - **Accruals for clinical and manufacturing vendors** — Operating expenses and liabilities - **Impairment of licensed technology or intangibles** — Balance sheet carrying values and earnings - **Stock-based compensation** — Operating expense and diluted share count - R&D expense timing affects reported operating losses - Clinical trial accruals depend on estimated vendor and site costs - Manufacturing and assay development costs may be expensed as incurred - Licensed technology and acquired intangibles may require impairment testing - Stock-based compensation can materially affect non-cash expenses --- *Last updated: 2026-04-29T04:47:48.791680+00:00*